← Back to Search

Unknown

A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus

Phase 2
Waitlist Available
Research Sponsored by Carmot Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years

Summary

This trial is testing a new treatment called CT-868 to see if it can help lower blood sugar levels in overweight and obese people with type 2 diabetes.

Eligible Conditions
  • Diabetes
  • Obesity

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: CT-868 Maximum Tolerated DoseExperimental Treatment1 Intervention
CT-868
Group II: CT-868 Low DoseExperimental Treatment1 Intervention
CT-868
Group III: PlaceboPlacebo Group1 Intervention
Placebo

Find a Location

Who is running the clinical trial?

Carmot Therapeutics, Inc.Lead Sponsor
7 Previous Clinical Trials
1,210 Total Patients Enrolled
1 Trials studying Obesity
450 Patients Enrolled for Obesity
Michael ElliottStudy DirectorCarmot Therapeutics, Inc.
5 Previous Clinical Trials
400 Total Patients Enrolled
~25 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top